CA2358508A1 - Applications therapeutiques de polypeptides flint - Google Patents
Applications therapeutiques de polypeptides flint Download PDFInfo
- Publication number
- CA2358508A1 CA2358508A1 CA002358508A CA2358508A CA2358508A1 CA 2358508 A1 CA2358508 A1 CA 2358508A1 CA 002358508 A CA002358508 A CA 002358508A CA 2358508 A CA2358508 A CA 2358508A CA 2358508 A1 CA2358508 A1 CA 2358508A1
- Authority
- CA
- Canada
- Prior art keywords
- mflint
- cells
- arg
- flint
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
la protéine FLINT mature (mFLINT) se lie avec FasL et LIGHT, et empêche une interaction FasL-Fas. La protéine mature mFLINT inhibe l'activité apoptotique et pro-inflammatoire à médiation FasL-Fas, et convient pour le traitement de troubles associés à une apoptose et à une inflammation anormales. L'invention concerne des séquences d'amino-acides et de nucléotides de FLINT et de FLINT mature. Elle porte également sur des compositions thérapeutiques et sur des méthodes de traitement faisant intervenir mFLINT.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11340798P | 1998-12-22 | 1998-12-22 | |
US60/113,407 | 1998-12-22 | ||
PCT/US1999/006797 WO1999050413A2 (fr) | 1998-03-30 | 1999-03-30 | APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF |
USPCT/US99/06797 | 1999-03-30 | ||
US17223999P | 1999-10-20 | 1999-10-20 | |
US60/172,239 | 1999-10-20 | ||
PCT/US1999/030734 WO2000037094A2 (fr) | 1998-12-22 | 1999-12-21 | Applications therapeutiques de polypeptides flint |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2358508A1 true CA2358508A1 (fr) | 2000-06-29 |
Family
ID=27378725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002358508A Abandoned CA2358508A1 (fr) | 1998-12-22 | 1999-12-21 | Applications therapeutiques de polypeptides flint |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140138A2 (fr) |
JP (1) | JP2003520761A (fr) |
AU (1) | AU2211100A (fr) |
CA (1) | CA2358508A1 (fr) |
WO (1) | WO2000037094A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69837996T2 (de) | 1997-01-14 | 2008-02-28 | Human Genome Sciences, Inc. | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta |
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
WO2002009668A2 (fr) * | 2000-08-02 | 2002-02-07 | Eli Lilly And Company | Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire |
GB202016058D0 (en) * | 2020-10-09 | 2020-11-25 | Ucl Business Ltd | Therapeautic treatment |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69837996T2 (de) * | 1997-01-14 | 2008-02-28 | Human Genome Sciences, Inc. | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta |
US5885800A (en) * | 1997-02-04 | 1999-03-23 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor, TR4 |
AU9013998A (en) * | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
EP1019502A2 (fr) * | 1997-08-06 | 2000-07-19 | Regeneron Pharmaceuticals, Inc. | Nouveau recepteur orphelin |
EP1015587B1 (fr) * | 1997-09-18 | 2008-04-23 | Genentech, Inc. | HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3 |
AU1535699A (en) * | 1997-11-24 | 1999-06-15 | Apotech S.A. | Novel receptors opg-2 |
AU3369199A (en) * | 1998-03-30 | 1999-10-18 | Eli Lilly And Company | Therapeutic applications of mature flint (mflint) polypeptides or opg3, a memberof the tnf receptor superfamily |
-
1999
- 1999-12-21 EP EP99966602A patent/EP1140138A2/fr not_active Withdrawn
- 1999-12-21 AU AU22111/00A patent/AU2211100A/en not_active Abandoned
- 1999-12-21 JP JP2000589204A patent/JP2003520761A/ja not_active Withdrawn
- 1999-12-21 WO PCT/US1999/030734 patent/WO2000037094A2/fr not_active Application Discontinuation
- 1999-12-21 CA CA002358508A patent/CA2358508A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000037094A3 (fr) | 2000-11-09 |
JP2003520761A (ja) | 2003-07-08 |
AU2211100A (en) | 2000-07-12 |
EP1140138A2 (fr) | 2001-10-10 |
WO2000037094A2 (fr) | 2000-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040167074A1 (en) | Therapeutic applications of mFLINT polypeptides | |
Brines et al. | Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response | |
EP0885299B1 (fr) | Recepteur et ligands ob | |
JP4411330B2 (ja) | 腫瘍壊死因子関連リガンド | |
EP1326974B1 (fr) | Procedes relatifs a l'utilisation de polypeptide lie a l'interleukine 17 (il-17) humaine pour le traitement de maladies- | |
JP3750819B2 (ja) | C−kit受容体に対するリガンド及びその使用法 | |
WO1997047321A1 (fr) | Utilisation de proteines chimeres regulatrices du complement du virus vaccinal pour inhiber ledit complement | |
US6475781B1 (en) | Trans-dominant suppressor genes for oligomeric proteins | |
JP2005506287A5 (fr) | ||
CA2181566C (fr) | Compositions et methodes utilisant un recepteur mpl non lie pour stimuler la production de plaquettes | |
JP2005506287A (ja) | 造血障害を治療するためのlp82の使用 | |
US20020069422A1 (en) | New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology | |
CA2358508A1 (fr) | Applications therapeutiques de polypeptides flint | |
US6207454B1 (en) | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide | |
US7537932B1 (en) | Antibodies that bind purified mammalian FLT3 ligands | |
EP0977859B1 (fr) | Facteur neurotrophique nnt-1 | |
ZA200005157B (en) | Therapeutic applications of mature flint (mFLINT) polypeptides or OPG3, a member of the TNF receptor superfamily. | |
US20040236088A1 (en) | Novel polypeptide analogs and fusions and their methods of use | |
MXPA00009523A (en) | THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY | |
WO2001028582A2 (fr) | Applications therapeutiques de polypeptides de flint | |
RU2258710C2 (ru) | Новый цитокин zalpha11-лиганд | |
US20040072745A1 (en) | Therapeutic methods of use for lp229 | |
KR100409099B1 (ko) | 신경 손상 치료 기구 | |
WO1998055141A9 (fr) | Procedes et produits pour induire l'apoptose des cellules neuroendocrines a l'aide de proteine stimulant les macrophages | |
WO2003065981A2 (fr) | Methodes d'utilisation therapeutiques de lp229 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |